When we examine vicarious trauma in Latino and other communities of color, we cannot separate individual experience from the ...

Welcome to Onc Nurse On Call, the new podcast from Oncology Nursing News, hosted by editors-in-chief Patricia Jakel, MN, RN, ...

Deborah (Debi) A. Boyle MSN, RN, AOCNS, FAAN, is editor in chief of Oncology Nursing News®. She is a long tenured oncology clinical nurse specialist who has practiced in both Comprehensive Cancer ...

Look back at the top 5 updates for oncology nurses and advanced practices providers published in 2025. From clinical updates ...

The APP ordered a bilateral diagnostic mammogram and left breast ultrasound that revealed extremely dense breast tissue, a ...

This episode’s guest, Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, a clinical nurse specialist at Norris Comprehensive ...

Melinda Mayorga, RN, MSN, CNS, AGCNS-BC, OCN, is a clinical nurse specialist at Norris Comprehensive Cancer Center University of Southern California in Los Angeles. Melinda Mayorga, RN, MSN, CNS, ...

The treatment combination of T-DXd and pertuzumab was granted FDA approval in the first-line for unresectable or metastatic HER2-positive breast cancer. The FDA has approved fam-trastuzumab deruxtecan ...

Patients with relapsed/refractory large B-cell lymphoma treated with glofitamab or epcoritamab experienced early disease progression. Most disease progression in patients with relapsed/refractory ...

Six-month complete response with frontline axicabtagene ciloleucel predicts long-term survival in patients with high-risk large B-cell lymphoma. Patients with high-risk large B-cell lymphoma (LBCL) ...

Phase 3 trial results demonstrated a significant benefit with the BTK inhibitor pirtobrutinib vs bendamustine plus rituximab in patients with untreated CLL/SLL. Pirtobrutinib (Jaypirca) showed a ...